Royal Bank of Canada’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,095
| Closed | -$2K | – | 7251 |
|
|
2024
Q1 | $2K | Sell |
1,095
-11,729
| -91% | -$21.4K | ﹤0.01% | 6283 |
|
|
2023
Q4 | $11K | Buy |
12,824
+3,633
| +40% | +$3.12K | ﹤0.01% | 5939 |
|
|
2023
Q3 | $10K | Buy |
9,191
+4,644
| +102% | +$5.05K | ﹤0.01% | 5935 |
|
|
2023
Q2 | $12K | Buy |
4,547
+1,057
| +30% | +$2.79K | ﹤0.01% | 5973 |
|
|
2023
Q1 | $14K | Sell |
3,490
-2,052
| -37% | -$8.23K | ﹤0.01% | 5794 |
|
|
2022
Q4 | $28K | Buy |
5,542
+2,347
| +73% | +$11.9K | ﹤0.01% | 5696 |
|
|
2022
Q3 | $41K | Buy |
3,195
+2,490
| +353% | +$32K | ﹤0.01% | 5348 |
|
|
2022
Q2 | $9K | Sell |
705
-1,609
| -70% | -$20.5K | ﹤0.01% | 5973 |
|
|
2022
Q1 | $36K | Sell |
2,314
-3,373
| -59% | -$52.5K | ﹤0.01% | 5810 |
|
|
2021
Q4 | $100K | Buy |
5,687
+2,792
| +96% | +$49.1K | ﹤0.01% | 5414 |
|
|
2021
Q3 | $60K | Buy |
2,895
+738
| +34% | +$15.3K | ﹤0.01% | 5542 |
|
|
2021
Q2 | $43K | Buy |
2,157
+507
| +31% | +$10.1K | ﹤0.01% | 5646 |
|
|
2021
Q1 | $48K | Buy |
+1,650
| New | +$48K | ﹤0.01% | 5423 |
|
|
2020
Q2 | – | Sell |
-933,959
| Closed | -$11.5M | – | 6400 |
|
|
2020
Q1 | $11.5M | Sell |
933,959
-1,716
| -0.2% | -$21.2K | 0.01% | 1072 |
|
|
2019
Q4 | $17.3M | Sell |
935,675
-272,692
| -23% | -$5.04M | 0.01% | 1066 |
|
|
2019
Q3 | $16.7M | Sell |
1,208,367
-66
| -0% | -$914 | 0.01% | 1023 |
|
|
2019
Q2 | $17.7M | Buy |
+1,208,433
| New | +$17.7M | 0.01% | 1032 |
|